Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This clinical trial is an open-label, multicenter, prospective phase 2 clinical trial targeting pediatric leukemia patients of infant age. The goal is to improve survival rates by varying the presence or absence of chemotherapy and hematopoietic stem cell transplantation based on genetic characteristics at the time of diagnosis and minimal residual disease (MRD) values measured by various methods after treatment. In addition, by clearly defining the patient group that requires hematopoietic stem cell transplantation, it is expected that the role of hematopoietic stem cell transplantation in infantile leukemia, for which there have been various guidelines for hematopoietic stem cell transplantation, can be confirmed. Additionally, due to the characteristics of infants, this study aim to identify long-term sequelae or prognosis related to treatment by prospectively collecting side effect data related to treatment during and after treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dziecko ma mniej niż 1 rok w momencie diagnozy.
- •Dziecko ma zdiagnozowaną ostrą białaczkę limfoblastyczną (ALL) lub ostrą białaczkę z dominacją limfocytów (ALAL).
- •Rodzice (opiekunowie) wyrazili zgodę na udział dziecka w badaniu.
✗ Disqualifies
- •Dziecko ma inną odmianę białaczki niż ALL lub ALAL.
- •Dziecko ma zespół Downa, zespół Blooma, ataksję-teleangiektazję, anemię Fanconiego, zespół Kostmanna, zespół Shwachmana lub inne choroby szpiku.
- •Dziecko przechodziło wcześniej przeszczep komórek macierzystych.
- •Dziecko choruje na białaczkę, która powróciła.
- •Dziecko otrzymało leki steroidowe w ciągu ostatnich 4 tygodni (chyba że było to w nagłym przypadku onkologicznym po ustaleniu diagnozy i grupy ryzyka).
Simplified criteria — AI translation
Trial details
- Maximum age
- 2 Years
- Last updated (source)
- July 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (10)
Kyungpook National University Chilgok-Hospital
Daegu, South Korea
Chungnam National University Hospital
Daejeon, South Korea
Chonnam National University Hwasun Hospital
Hwasun, South Korea
Jeju National University Hospital
Jeju City, South Korea
Pusan National University Yangsan Hospital
Pusan, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Cente
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Seoul saint Mary's Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Trial contact
Ji Yoon Kim, Professor
Yeon Jung Lim, Professor
Hee Jo Baek
Hyun Sik Kang
Eu Jeen Yang
Ho Joon Im, MD
Hee Young Ju, MD
Hyoung Jin Kang, MD
Jae Wook Lee, MD
seung min Hahn, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/31/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.